Apollomics (APLM) AI Stock Analysis

• Market Cap: $7.12M
• Dividend Yield: N/A
• Average Volume (3M): 44.83K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.75
• Revenue Growth: N/A
• EPS Growth: -1786.46%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -52.80
• Shares Outstanding: 1,103,348
• 10 Day Avg. Volume: 25,375
• 30 Day Avg. Volume: 44,827
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.20
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -11.31
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Apollomics' stock score is primarily impacted by its financial instability, characterized by persistent losses and high leverage. While there are slight technical indicators of improvement, the negative P/E ratio and absence of dividends present valuation challenges. Overall, the stock's speculative nature and financial concerns result in a low score.

Apollomics Business Overview & Revenue Model

Company Description

Apollomics, Inc. (APLM) is a biopharmaceutical company focused on the discovery and development of novel oncology therapies. The company operates in the healthcare sector, specifically targeting the treatment of cancers through innovative drug development. Apollomics' core products include a pipeline of small-molecule and biologic drug candidates designed to address unmet medical needs in oncology.

How the Company Makes Money

Apollomics primarily generates revenue through the development and commercialization of its oncology drug candidates. The company's revenue streams include milestone payments and royalties from partnerships with other pharmaceutical companies. Additionally, Apollomics may generate income from licensing its proprietary technologies and intellectual property to third parties. Significant partnerships with larger pharmaceutical firms can provide funding for drug development and potential co-marketing opportunities, contributing to its earnings.

Apollomics Financial Statement Overview

Summary

Apollomics demonstrates significant financial challenges with persistent losses, high leverage, and negative cash flows. Despite slight improvements in equity and revenue growth, the company struggles with profitability and cash flow generation.

Income Statement

Apollomics shows a consistent pattern of negative profitability with significant net losses over multiple years. The company reported a negative gross profit margin and declining EBIT and EBITDA margins. While there is revenue growth from 2022 to 2023, the overall financial health in terms of profitability remains weak.

Balance Sheet

The balance sheet indicates a high level of liabilities relative to equity, resulting in a negative debt-to-equity ratio historically. Although the equity improved to positive in 2023, which is a positive sign, the overall leverage remains a concern. The equity ratio is relatively low for the biotechnology industry, suggesting potential financial instability.

Cash Flow

Cash flows are challenging, with negative operating cash flow and free cash flow across the years. There was a slight improvement in 2023's free cash flow growth rate, but the operating cash flow to net income ratio indicates inefficiencies in turning income into cash. Cash flow management remains a crucial area for improvement.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
821.00K	323.00K	2.00K	1.84M	0.00
	Gross Profit
127.00K	-452.00K	-679.00K	1.23M	-369.00K
	EBIT
-54.83M	-240.21M	-91.75M	-74.08M	-24.75M
	EBITDA
-171.75M	-239.94M	-94.03M	-74.22M	-45.34M
	Net Income Common Stockholders
-172.60M	-240.81M	-94.80M	-74.82M	-45.91M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
37.82M	54.61M	94.48M	154.39M	74.12M
	Total Assets
55.39M	76.47M	123.44M	169.94M	79.05M
	Total Debt
4.66M	991.00K	1.04M	1.51M	135.97M
	Net Debt
-27.39M	-31.68M	-45.70M	-129.13M	97.48M
	Total Liabilities
14.15M	524.60M	336.30M	297.87M	139.78M
	Stockholders Equity
41.23M	-448.12M	-212.86M	-127.93M	-60.72M
Cash Flow		Free Cash Flow
-43.22M	-43.19M	-50.86M	-45.83M	-22.80M
	Operating Cash Flow
-43.21M	-42.82M	-43.31M	-35.68M	-21.94M
	Investing Cash Flow
21.36M	29.05M	-38.95M	2.33M	-29.86M
	Financing Cash Flow
21.23M	-294.00K	-1.64M	125.51M	9.51M

Apollomics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APLM, the sentiment is Positive. The current price of 6.45 is above the 20-day moving average (MA) of 6.09, below the 50-day MA of 6.97, and below the 200-day MA of 11.11, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 50.59 is Neutral, neither overbought nor oversold. The STOCH value of 59.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for APLM.

Apollomics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.36B	3.88	-42.93%	2.87%	17.85%	1.45%
APLM	42 Neutral	$7.12M	―	-233.67%	―	―	-1786.46%
SNGX	39 Underperform	$6.06M	―	-248.97%	―	―	57.83%
SLXN	34 Underperform	$8.69M	―		―	―	-73095.97%
MTVA	33 Underperform	$15.92M	―	-224.18%	―	―	-75.88%
RNAZ	27 Underperform	$13.16M	―	-490.03%	―	―	99.64%